Plasma Protein Therapeutics Market Expected to Reach $44.3 Billion by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Plasma Protein Therapeutics Market," The plasma protein therapeutics market was valued at $26.5 billion in 2021, and is estimated to reach $44.3 billion by 2031, growing at a CAGR of 5.2% from 2022 to 2031.

The plasma protein therapeutics market is expected to grow as a result of factors including an increase in R&D activities related to plasma protein therapeutics and support for such research in various countries. These medications particularly replace proteins, enabling patients to live healthier and more productive lives. The plasma protein treatments majorly treat diseases and conditions such as chronic diseases. For instance, in October 2019, ADMA Biologics, Inc. a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and the prevention of certain infectious diseases, announced the first commercial sales of ASCENIV (formerly known as RI-002).  ASCENIV received approval from the U.S. Food and Drug Administration (“FDA”) on April, 2019.  ASCENIV is used for the treatment of primary humoral immunodeficiency (PI) in adults and adolescents.

For an instance, in September 2022, Grifols a global leader in plasma medicines announced it has signed a pioneering long-term agreement with Canadian Blood Services, Canada’s national blood authority, to greatly increase the country’s self-sufficiency in immunoglobulin (Ig) medicines, essential plasma-protein therapies used to treat a wide range of immunodeficiencies and other medical conditions. Thus, adoption of such strategies drives the market growth.  Thus, significant product launches fuel the market growth.  

In addition, increase in prevalence of autoimmune disorders is the upcoming plasma protein therapeutics market trends. Conversely strict regulation regarding collection, processing, and distribution of plasma protein products are expected to restrain the market growth.  

Technological advancement is a major opportunity for the growth of the plasma protein therapeutics market. Advances in technology and research have enabled the development of new and innovative plasma protein therapeutics that offer improved outcomes for patients. In addition, advancements in analytical and diagnostic technologies have enabled the development of targeted plasma protein therapeutics that can be used to treat specific diseases. These targeted treatments offer improved outcomes for patients by targeting specific molecules involved in the disease process, rather than using a more general approach. Technological advancements represent a significant opportunity for the growth of the plasma protein therapeutics market, and continued investment in research and development is expected to lead to further advancements during the forecast period

Depending on product type, the market is divided into immunoglobulin, albumin, plasma derived factor VIII, coagulation factor, and others. The immunoglobulin segment accounted for largest plasma protein therapeutics market size in 2021 and is expected to witness highest CAGR during the forecast period owing to increase in availability of innovative immunoglobulin products and developments in therapeutic administration, such as the subcutaneous immunoglobulin products. 

On the basis of application, the plasma protein therapeutics market analysis is classified into hemophilia, idiopathic thrombocytopenia purpura, primary immunodeficiency and others. The hemophilia segment dominated the plasma protein therapeutics market size in 2021 owing to the rise in people diagnosed with hemophilia and increase in availability of plasma protein therapeutics options for hemophilia. Primary immunodeficiency is projected to register a CAGR during the forecast period, owing to rise in awareness regarding use of plasma protein therapeutics for the treatment of the primary immunodeficiency and their high prevalence.  

On the basis of end user, the market is categorized into hospitals and others. The hospitals segment occupied highest plasma protein therapeutics market share in 2021 owing to increase in number of patient visits in hospitals suffering from autoimmune conditions such as hemophilia and ease of access of protein therapeutics in hospital. The  others segment is  projected to register highest CAGR of owing to cost effectiveness, and ease of scheduling visits.   

Region wise, North America held the highest plasma protein therapeutics market share in 2021, and is expected to maintain its lead during the forecast period, owing to rise in investments for plasma protein therapeutics research, increase in cases of rare diseases and high prevalence of immunological disorders. However, Asia-Pacific is expected to witness highest growth during the plasma protein therapeutics market forecast period, owing to enhancements in healthcare facilities and improvements in patient awareness about plasma protein therapeutics drugs. 

Key findings of the study  

• By product type, the immunoglobulin segment was highest contributor to the plasma protein therapeutics industry in 2021 with highest CAGR during the forecast period.  
• By application, the hemophilia segment dominated the plasma protein therapeutics industry in 2021. However, primary immunodeficiency is anticipated to grow at highest CAGR during the forecast period.  
• On the basis of end user, the hospital segment was dominated the market in 2021. However, others segment is anticipated to grow at the highest CAGR of 5.6 % during the forecast period  
• Region wise, North America generated the largest revenue in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR of 6.0 % during the forecast period.